Trial | NCT00846976  Report issue

Title

Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer
A Treatment Protocol to Monitor the Safety of a 200 mg Daily Dose of Bicalutamide (Casodex) in Patients With Advanced Prostate Cancer

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    101
This is an open label, single-centered treatment protocol designed to monitor the safety of patients treated with a 200 mg daily dose of CASODEX. Patient will receive CASODEX as long as physician feels that he is benefiting from this form of therapy.
Study Started
Dec 31
1994
Primary Completion
Jun 30
2013
Study Completion
Jun 30
2013
Last Update
Jan 21
2015
Estimate

Drug Bicalutamide

200mg daily

  • Other names: Casodex

200 mg Casodex Experimental

Criteria 

Inclusion Criteria:

Histologically or cytologically confirmed adenocarcinoma of the prostate gland
Patients with advanced prostate cancer
Adult male over the age of 18 years old
Normal liver function (AST < 2 x Upper Limit Normal)

Exclusion Criteria:

ECOG performance status of 4.
Previous history or presence of another malignancy other than prostate cancer or treated squamous/basal cell carcinoma of the skin, within the last 5 years.
No Results Posted